WT1 and neoplasm: Another dendritic cell vaccine with WT1 protein mRNA (NCT01291420) showed striking tumor reduction (ORR) in 50% of 40 hormone receptor-negative/HER2-negative metastatic breast cancer (HR−/HER2 − MBC) patients at 6 months posttreatment.